The self testing market has seen considerable growth due to a variety of factors.
• In recent times, the self-testing market has seen accelerated expansion. The size of the market which was at $15.28 billion in 2024 is projected to hit $16.9 billion in 2025, marking a compound annual growth rate (CAGR) of 10.6%.
The significant growth experienced in the past can be traced back to the impacts of educational reforms, advancements in scientific research, the industrial revolution, breakthroughs in healthcare and preventive medicine as well as the emergence of psychometric testing and personality assessment.
The self testing market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations are high for a swift expansion of the self-testing market in the upcoming years. It's predicted to inflate to a high of $24.99 billion by 2029, with a compound annual growth rate (CAGR) of 10.3%.
Advancements in personalized medicine, the emergence and growth of telehealth and remote monitoring, heightened demand for mental health services, along with the rapid expansion of wearable health tech, account for the expected growth surge during this forecast period. Key trends projected to shape this market in the forecast period range from point-of-care testing to blockchain-aided data security, individualized wellness ecosystems to biohacking, and quantified self-movements.
The escalating occurrence of persistent illnesses is anticipated to boost the expansion of the self-testing market in the future. Chronic illnesses are defined as enduring medical conditions that usually develop gradually and continue for a prolonged duration. They are caused due to changes in demographics, lifestyle behaviors, environmental factors, and advancements in healthcare. Self-testing is employed in managing chronic illnesses to actively supervise health, enhance compliance with treatment regimes, and enable the early discovery of any potential complications or alterations in the condition. For example, the National Library of Medicine, a renowned US-based medical library, reported in January 2023 that by 2050, the number of individuals suffering from at least one chronic disease is expected to reach 142.66 million, which marks a 99.5% increase from 71.522 million in 2020. Therefore, the rising occurrence of chronic diseases is propelling the expansion of the self-testing market.
The self-testing market covered in this report is segmented –
1) By Product: Kits, Devices, Strips
2) By Sample Type: Blood, Urine, Stool, Other Sample Types
3) By Distribution Channel: Online, Offline
4) By Application: Blood Glucose Testing, Pregnancy And Fertility Testing, Cancer Testing, Drug Abuse Testing, Sexually Transmitted Disease Or Sexually Transmitted Infection Testing, Cholesterol Testing, HIV Testing, Thyroid Testing, Other Applications
Subsegments:
1) By Kits: Blood Glucose Testing Kits, Pregnancy Test Kits, Ovulation Test Kits, HIV Test Kits, COVID-19 Test Kits, Allergy Test Kits, Cholesterol Test Kits
2) By Devices: Blood Glucose Meters, Thermometers (Digital, Infrared), Blood Pressure Monitors, Pulse Oximeters, ECG Or EKG Monitors, Pregnancy Test Devices (Electronic), Home Hearing Test Devices
3) By Strips: Blood Glucose Test Strips, Urine Test Strips, Pregnancy Test Strips, Ovulation Test Strips, Cholesterol Test Strips, Urinary Tract Infection (UTI) Test Strips, Ketone Test Strips
Key players in the self-test market, such as Cervicheck's self-sampling kits, are prioritizing the design of innovative solutions that offer users more convenience, accessibility, and precision. This medical tool lets individuals gather their own biological specimens, such as blood, saliva, urine, or tissue, for diagnosis or testing. An example of this is when Pragmatech Healthcare Solutions, a biotechnology firm from India, unveiled Cervicheck in April 2023. This self-test kit enables women to screen for the human papillomavirus (HPV), believed to be a major contributor to cervical cancer cases. With this kit, women can collect samples from the comfort of their homes, helping to solve issues with delayed diagnosis due to hesitation in having samples collected at hospitals or clinics. It includes self-sampling and point-of-care detection features. Moreover, this kit represents a significant stride in empowering women to detect cervical cancer in the early stages, with the goal of decreasing death rates and the strain of late cancer detection.
Major companies operating in the self-testing market are:
• Roche Diagnostics
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Siemens Healthineers
• Becton Dickinson and Company
• Hologic Inc.
• PerkinElmer
• BioMérieux
• Sysmex Corporation
• Bio-Rad Laboratories
• Quidel Corporation
• Cepheid
• OraSure Technologies
• Meridian Bioscience Inc.
• Ancestry.com DNA LLC
• 23andMe Inc.
• MyHeritage Ltd.
• iHealth Labs Inc.
• Everly Health Inc.
• Helix OpCo LLC
• BioIQ Inc.
• Veritas Intercontinental Inc.
• Pathway Genomics Corporation
• Vitagene Inc.
• Orig3n Inc.
North America was the largest region in the self-testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the self-testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.